Tomer Berkovitz

Background

Dr. Tomer Berkovitz, PhD, is a Managing Partner at aMoon, a global healthcare and life sciences venture fund headquartered in Ra’anana, Israel, with offices in Boston ¹². He joined aMoon in February 2018 and co-leads the firm’s Growth Fund ¹³.

Before aMoon, Berkovitz spent approximately six years as an investment banker at J.P. Morgan in New York, where he was promoted to Executive Director — reportedly in record time — and led healthcare transactions within the Corporate Finance Advisory team, advising senior management and boards of S&P 500 healthcare firms on capital markets and M&A ¹⁴⁵. He was then appointed Chief Financial Officer of Alcobra Ltd. (NASDAQ: ADHD), an Israeli biopharmaceutical company, effective May 1, 2014, reporting to CEO Dr. Yaron Daniely ⁴⁵. At Alcobra, he was promoted to Chief Operating Officer in addition to CFO, led public equity offerings, and oversaw the company’s merger with Arcturus Therapeutics ¹⁵. Notably, Dr. Yaron Daniely, Berkovitz’s former CEO at Alcobra, is now a General Partner and Head of aMoon Alpha at the same firm ².

From 2000 to 2003, Berkovitz served as an economist in the Financial Advisory Unit to the Chief of Staff of the Israel Defense Forces ⁶.

Berkovitz earned his Ph.D. in Finance (with Distinction) from Columbia Business School, where he published research in leading academic journals including Management Science and the Journal of Applied Corporate Finance ¹⁷⁸. His published works include “Innovation in Business Groups” (Management Science, 2010, co-authored with Sharon Belenzon) and “Intracompany Governance and Innovation” (NBER Working Paper, 2009, co-authored with Sharon Belenzon and Patrick Bolton) ⁷⁸. He also holds an M.Sc. in Finance and Accounting (Magna Cum Laude) and a B.A. in Economics and Management (Magna Cum Laude), both from Tel Aviv University ¹.

At aMoon, Berkovitz spearheads the firm’s “Bridge to Wall Street” function, managing relationships with major investment banks, equity research analysts, and institutional investment funds — a role that leverages his 15+ years of U.S. capital markets experience ¹. He has led investments and served on the board of directors of Seer (NASDAQ: SEER), SOPHiA GENETICS (NASDAQ: SOPH), Sera Prognostics (NASDAQ: SERA), PrognomIQ, Zebra Medical Vision (acquired by Nanox, NASDAQ: NNOX), Omada Health (NASDAQ: OMDA), MetaSight Diagnostics, and Positive Development ^19101112.

Stated Thesis

(Self-reported: These represent what Berkovitz says publicly about his investing approach. See Inferred Thesis for analysis of actual investment behavior.)

Berkovitz has described the healthcare technology market as undergoing a genuine revolution, stating: “The question is always going to be where is the valuation relative to the maturity of the revolution. The market is getting ahead of the curve. But the revolution is real” ¹³.

On technology’s role in care delivery, he has stated: “Unless you crack the technology aspect of this, you’re not going to be able to provide the kind of care that is needed” ¹⁴.

Regarding investment criteria, Berkovitz emphasizes the convergence of technology and biology — consistent with aMoon’s firm-wide thesis — and has highlighted platform technologies that can be transformative across multiple clinical domains. On Seer’s proteomics platform, the aMoon team (including Berkovitz) wrote: “We believe the company has developed a transformative technology, which will enable the next scientific revolution” ¹⁵. On SOPHiA GENETICS, he wrote: “The value in personalized medicine lies in the shift from hardware to software, and Sophia has the potential to dominate the software side” ⁹.

He has also emphasized outcomes-based and cost-reducing models in digital health. On investing in Omada Health, he stated: “Omada Health’s dedication to health outcomes and mindset-driven care support was a major differentiator that stood out to aMoon in a crowded digital health landscape” ¹⁶. On Positive Development’s autism care model, he noted: “Many families are looking for alternative clinical approaches. And when you talk to payers, they can’t really bear the cost of paying for 1.8 million kids with autism with the ABA approach” ¹⁴.

aMoon Growth, which Berkovitz co-leads, typically invests $10-30 million initially in companies at specific inflection points: biotech/medtech companies with clinical proof of concept, diagnostics companies approaching commercialization, and digital health companies with initial repeat revenues ready to scale ¹⁷.

Inferred Thesis

Based on 12 verified investments personally led by or specifically attributed to Berkovitz (from press releases, board disclosures, and aMoon’s website), the following patterns emerge. Note: Berkovitz co-leads aMoon’s Growth Fund, which has made 40+ investments total; this analysis covers only deals where his personal involvement is confirmed.

Sector allocation (12 confirmed Berkovitz-led investments): - Diagnostics, proteomics, and genomics: 5 of 12 (42%) — Seer, SOPHiA GENETICS, Sera Prognostics, PrognomIQ, MetaSight Diagnostics - Digital health and care delivery: 3 of 12 (25%) — Omada Health, Positive Development, Zebra Medical Vision - Therapeutics and biopharma: 2 of 12 (17%) — Character Biosciences, Alcobra/Arcturus (pre-aMoon) - AI diagnostics / medical imaging: 2 of 12 (17%) — Zebra Medical Vision, MetaSight Diagnostics

Stage distribution (12 confirmed investments): - Series D and later: 5 of 12 (42%) — Seer (Series D), SOPHiA GENETICS (Series F), Sera Prognostics (Series E), Omada Health (Series E), Positive Development (Series C) - Series A-B: 4 of 12 (33%) — PrognomIQ (Series B), Zebra Medical Vision (Series C), MetaSight (Series A), Character Biosciences (Series B) - Growth / Pre-IPO: 3 investments with confirmed IPO pathway involvement (Seer, SOPHiA GENETICS, Omada Health)

Key patterns:

• Platform technology orientation: Berkovitz disproportionately invests in platform companies rather than single-asset plays. Seer (proteomics platform), SOPHiA GENETICS (genomic analysis software), and PrognomIQ (multi-cancer early detection) all have platform architectures applicable across multiple diseases ⁹¹⁵¹⁸.

• IPO pathway specialist: Berkovitz’s Wall Street background makes him unusual among healthcare VCs. Of 12 confirmed investments, 4 have gone public (Seer, SOPHiA GENETICS, Sera Prognostics, Omada Health) and 1 was acquired (Zebra Medical Vision by Nanox). His “Bridge to Wall Street” role at aMoon explicitly focuses on guiding portfolio companies through public offerings ¹.

• Board-active investor: Confirmed board seats at Seer, SOPHiA GENETICS (since March 2021, also chairs Strategy Committee), Sera Prognostics, PrognomIQ (Director), Zebra Medical Vision, MetaSight Diagnostics, and Positive Development — 7 of 12 confirmed investments ^39101112. This is an unusually high board-seat-to-investment ratio, suggesting deeply hands-on involvement.

• Diagnostics-heavy within healthcare: While aMoon as a firm invests heavily in therapeutics (26% of firm portfolio), Berkovitz’s personal deal attribution skews much more toward diagnostics and life science tools (42%), suggesting he is the firm’s diagnostics specialist.

• Geographic pattern: Of confirmed investments, approximately half are US-based (Seer, PrognomIQ, Omada Health, Positive Development, Sera Prognostics, Character Biosciences) and half Israel-based or international (SOPHiA GENETICS in Switzerland, Zebra Medical Vision and MetaSight in Israel), consistent with his Boston base and aMoon’s dual-geography strategy.

• Co-investor patterns: Berkovitz-led deals frequently involve large institutional co-investors: T. Rowe Price (Seer Series D), Fidelity (Omada Health Series E), Anthem (Sera Prognostics Series E), and B Capital/Flare Capital (Positive Development Series C) ^15161819.

Portfolio

Investments where Berkovitz’s personal involvement is confirmed through press releases, board disclosures, or aMoon attribution:

Notable exits: Seer IPO (NASDAQ: SEER, December 2020; aMoon invested at $228M valuation, IPO at $1.3B — approximately 15x return for aMoon) ²³; SOPHiA GENETICS IPO (NASDAQ: SOPH, July 2021; IPO at $1.1B+ valuation, 10 months after aMoon’s initial investment) ⁹²⁰; Zebra Medical Vision (acquired by Nanox for ~$200M, 2021) ²⁴; Omada Health IPO (NASDAQ: OMDA, June 2025; priced at $19/share, opened at $23) ²⁵; Sera Prognostics IPO (NASDAQ: SERA) ²¹.

Additional investments attributed to aMoon’s Growth Fund under Berkovitz’s co-leadership are listed in the aMoon firm profile. This table includes only deals with confirmed personal involvement.

In Their Own Words

“The question is always going to be where is the valuation relative to the maturity of the revolution. The market is getting ahead of the curve. But the revolution is real.” — Tomer Berkovitz, Bloomberg interview, December 2020 ¹³

“From our first conversation, my colleagues Dr. Reut Shema, Tamir Maxiner and I believed that Jurgi was a visionary the likes of which we at aMoon search every corner of the world to find.” — Tomer Berkovitz, aMoon blog, on SOPHiA GENETICS founder Jurgi Camblong ⁹

“The value in personalized medicine lies in the shift from hardware to software, and Sophia has the potential to dominate the software side.” — Tomer Berkovitz, aMoon blog ⁹

“Omada Health’s dedication to health outcomes and mindset-driven care support was a major differentiator that stood out to aMoon in a crowded digital health landscape. This latest funding round emphasizes our confidence in the Omada team and our strong belief in the company’s platform as a proven solution across multiple chronic conditions.” — Tomer Berkovitz, General Partner at aMoon Fund, GlobeNewsWire press release, February 2022 ¹⁶

“Unless you crack the technology aspect of this, you’re not going to be able to provide the kind of care that is needed.” — Tomer Berkovitz, Managing Partner at aMoon, on Positive Development’s approach to autism care, Behavioral Health Business, August 2025 ¹⁴

“Many families are looking for alternative clinical approaches. And when you talk to payers, they can’t really bear the cost of paying for 1.8 million kids with autism with the ABA approach that is so cumbersome it includes 40 hours of therapy a week.” — Tomer Berkovitz, Behavioral Health Business, August 2025 ¹⁴

“You can’t scale up and get the reimbursement and jeopardize the quality; that is the challenge.” — Tomer Berkovitz, on scaling healthcare delivery, Behavioral Health Business, August 2025 ¹⁴

“Our confidence in MetaSight’s innovative approach to diagnostics development and its potential to reshape the future of healthcare drives our investment.” — Tomer Berkovitz, Managing Partner at aMoon, GlobeNewsWire press release, November 2024 ¹¹

“These executive changes reflect the Board’s and Dr. Camblong’s long-term succession planning.” — Tomer Berkovitz, SOPHiA GENETICS Board Member and Managing Partner at aMoon Fund, on SOPHiA GENETICS CEO transition, PR Newswire, 2026 ²⁶

What Founders Say

Sean Duffy, Co-Founder and CEO of Omada Health, acknowledged aMoon’s role in the company’s $192 million Series E: “With the support of our investors, Fidelity, aMoon, Civilization Ventures and others, we’re able to better support our customer growth and usher in a new model of care” ¹⁶.

Mike Suiters, Co-Founder and CEO of Positive Development, stated regarding the $51.5M Series C co-led by aMoon: “The market is crying out for alternatives that are clinically effective, cost effective, and scalable. We’re in a unique position to help solve this problem” ¹⁹.

Prof. Tomer Shlomi, Founder and CEO of MetaSight Diagnostics, said upon aMoon’s investment and Berkovitz joining the board: “MetaSight’s unique prospective discovery and development methods provide an unbiased, comprehensive approach to identifying multi-omics diagnostic signatures” ¹¹.

No independently sourced founder testimonials specifically about Berkovitz’s personal value-add or working style were found through dedicated searching. The quotes above are from press releases associated with aMoon-led or aMoon-participated funding rounds and speak to the companies’ missions rather than Berkovitz’s individual investor qualities.

Connections

• Board member, SOPHiA GENETICS (NASDAQ: SOPH) — since March 2021; Chairman of Strategy Committee ³⁹
• Board member, Seer (NASDAQ: SEER) — led Series D investment ¹¹⁵
• Board member, Sera Prognostics (NASDAQ: SERA) — served on board following Series E investment ¹²¹
• Director, PrognomIQ — led Series B, serves on board ¹¹⁸
• Board member, Zebra Medical Vision — led Series C, served as board member prior to Nanox acquisition ¹
• Board member, MetaSight Diagnostics — joined board as part of Series A, November 2024 ¹¹
• Board member, Positive Development — joined board as part of Series C co-lead, July 2025 ¹²
• Advisory Board, Next Gen Diagnostics — alongside Dr. Clifford Reid (founding CEO, Travera/Complete Genomics) and Dr. Nathan Ledeboer ²⁷
• Former CFO & COO, Alcobra Ltd. (NASDAQ: ADHD, 2014-2017) — reported to Dr. Yaron Daniely (CEO), who is now General Partner & Head of aMoon Alpha ⁴⁵²
• Former Executive Director, J.P. Morgan — Healthcare Corporate Finance Advisory, New York ¹⁴
• Former IDF economist (2000-2003) — Financial Advisory Unit to the Chief of Staff of the Israel Defense Forces ⁶
• Co-investor relationships: T. Rowe Price (Seer), Fidelity (Omada Health), Anthem/Elevance (Sera Prognostics), B Capital and Flare Capital Partners (Positive Development) ^15161819

Sources